GSGTF: AI 评分 51/100 — AI 分析 (4月 2026)

GenSight Biologics S.A. is a clinical-stage biotechnology company focused on developing gene therapies for mitochondrial and neurodegenerative eye diseases. Their lead product, LUMEVOQ, targets Leber Hereditary Optic Neuropathy (LHON).

Key Facts: AI Score: 51/100 Sector: Healthcare

公司概况

概要：

GenSight Biologics S.A. is a clinical-stage biotechnology firm specializing in gene therapies for ocular and neurodegenerative diseases, primarily targeting mitochondrial dysfunction. Their lead candidate, LUMEVOQ, addresses Leber Hereditary Optic Neuropathy (LHON), positioning them in the forefront of innovative treatments for inherited blindness. The company operates within a competitive biotech landscape, focusing on unmet needs in ophthalmology.

GSGTF是做什么的？

GenSight Biologics S.A., founded in 2012 and headquartered in Paris, France, is a biotechnology company dedicated to discovering, developing, and commercializing gene therapies for mitochondrial and neurodegenerative diseases affecting the eye and central nervous system. The company operates through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its primary focus is on addressing significant unmet medical needs in inherited retinal diseases and neurodegenerative conditions. GenSight's lead product candidate, LUMEVOQ (GS010), is a recombinant adeno-associated viral vector serotype 2 (AAV2) based gene therapy currently in Phase III clinical trials for the treatment of Leber Hereditary Optic Neuropathy (LHON) caused by a mutated ND4 gene. LHON leads to a rapid loss of central vision, primarily affecting adolescents and young adults. The company is also developing GS030, which is in Phase I/II clinical trials for the treatment of retinitis pigmentosa and in the preclinical stage for dry age-related macular degeneration. GenSight's innovative approach leverages gene therapy to deliver functional genes directly to affected cells, aiming to restore or improve visual function. The company's pipeline includes preclinical programs targeting other ophthalmic and neurodegenerative diseases, demonstrating its commitment to expanding its therapeutic reach. GenSight Biologics employs 16 people.

GSGTF的投资论点是什么？

GenSight Biologics presents a high-risk, high-reward investment opportunity within the gene therapy space. The primary value driver is the potential approval and commercialization of LUMEVOQ for LHON, a market with limited treatment options. Positive Phase III clinical trial results and regulatory approval in Europe and the United States are key catalysts. The company's early-stage pipeline, including GS030, offers long-term growth potential. However, the company's negative profit margin of -1600% and reliance on a single lead product represent significant risks. Successful navigation of regulatory hurdles, effective commercialization strategies, and further pipeline development are crucial for realizing shareholder value. The company's market capitalization is approximately $40 million as of March 16, 2026.

GSGTF在哪个行业运营？

GenSight Biologics operates within the rapidly evolving biotechnology industry, specifically focusing on gene therapy for ophthalmic diseases. The gene therapy market is projected to experience significant growth, driven by technological advancements and increasing regulatory approvals. The competitive landscape includes companies like AGYTF (AGY Therapeutics), AVCTF (American CryoStem Corporation), BJTRF (Bio-jet Fuel Technology, Inc.), BOVNF (BiondVax Pharmaceuticals Ltd), and BPMUF (BPM Minerals Ltd), some of which are developing therapies for related conditions. GenSight's focus on mitochondrial diseases and optogenetics differentiates it within this competitive environment. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies.

Biotechnology

Healthcare

GSGTF有哪些增长机遇？

Expansion into New Therapeutic Areas: GenSight has the opportunity to leverage its gene therapy platform to target other ophthalmic diseases beyond LHON and retinitis pigmentosa. This includes exploring treatments for glaucoma, diabetic retinopathy, and other inherited retinal dystrophies. The market for these conditions is substantial, with millions of patients worldwide. Successful development and commercialization of therapies for these indications could significantly expand GenSight's revenue streams and market share. This expansion is contingent on successful preclinical and clinical trials, with a potential timeline of 3-5 years for new product launches.
Geographic Expansion: GenSight's initial focus is on securing regulatory approvals and commercializing LUMEVOQ in Europe and the United States. However, expanding into other geographic markets, such as Asia-Pacific and Latin America, presents a significant growth opportunity. These regions have large populations with unmet medical needs and increasing healthcare spending. Successful market entry requires navigating local regulatory requirements and establishing distribution partnerships. The timeline for geographic expansion is dependent on regulatory approvals and market access strategies, with potential entry into new markets within 2-4 years.
Strategic Partnerships and Collaborations: GenSight can accelerate its pipeline development and commercialization efforts through strategic partnerships and collaborations with larger pharmaceutical companies. These partnerships can provide access to additional funding, expertise, and distribution networks. Collaborations can also focus on co-developing new gene therapies or expanding the applications of existing technologies. Successful partnerships can de-risk the development process and enhance the company's long-term growth prospects. The timing of such partnerships is uncertain but could materialize within the next 1-2 years.
Advancements in Gene Therapy Technology: Continuous advancements in gene therapy technology, such as improved viral vectors and gene editing techniques, can enhance the efficacy and safety of GenSight's therapies. These advancements can also enable the development of treatments for a wider range of diseases. Investing in research and development to stay at the forefront of gene therapy innovation is crucial for maintaining a competitive advantage. These advancements are ongoing and could lead to significant breakthroughs in the next 3-5 years.
Orphan Drug Designations and Regulatory Incentives: GenSight's focus on rare genetic diseases allows it to benefit from orphan drug designations and other regulatory incentives, such as expedited review processes and market exclusivity. These incentives can reduce development costs and accelerate the time to market. Actively pursuing orphan drug designations for its pipeline products is a key growth strategy. The benefits of these designations are realized throughout the development and commercialization process, providing a sustained competitive advantage.

LUMEVOQ (GS010) is in Phase III clinical trials for Leber Hereditary Optic Neuropathy (LHON), a rare genetic disease causing vision loss.
GS030 is in Phase I/II clinical trials for retinitis pigmentosa, expanding the company's pipeline beyond LHON.
The company's gross margin is 100.0%, reflecting the high value of its potential gene therapy products, although this does not yet translate to overall profitability.
GenSight Biologics operates with 16 employees, indicating a lean organizational structure focused on research and development.
The company's beta of 0.81 suggests lower volatility compared to the overall market.

GSGTF提供哪些产品和服务？

Develops gene therapies for mitochondrial and neurodegenerative diseases.
Focuses on treatments for inherited retinal diseases and central nervous system disorders.
Utilizes gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms.
Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
Seeks regulatory approvals for its therapies in Europe and the United States.
Aims to commercialize its products and make them available to patients in need.
Engages in preclinical research to expand its pipeline of potential therapies.

GSGTF如何赚钱？

Develops and patents gene therapy technologies.
Conducts preclinical and clinical research to validate its therapies.
Seeks regulatory approval from agencies like the FDA and EMA.
Aims to commercialize approved therapies through partnerships or direct sales.

Patients with Leber Hereditary Optic Neuropathy (LHON).
Patients with retinitis pigmentosa.
Healthcare providers specializing in ophthalmology and neurology.
Hospitals and clinics offering gene therapy treatments.
Potential future patients with other mitochondrial and neurodegenerative diseases.

Proprietary gene therapy technology platforms.
Strong intellectual property portfolio with patents protecting its therapies.
Orphan drug designations providing market exclusivity.
First-mover advantage in developing gene therapies for specific rare diseases.

什么因素可能推动GSGTF股价上涨？

Upcoming: Potential regulatory approval of LUMEVOQ in Europe and the United States.
Upcoming: Results from ongoing clinical trials for GS030 in retinitis pigmentosa.
Upcoming: Announcement of strategic partnerships or collaborations.
Ongoing: Advancements in gene therapy technology.
Ongoing: Expansion into new therapeutic areas.

GSGTF的主要风险是什么？

Potential: Regulatory delays or rejection of LUMEVOQ.
Potential: Clinical trial failures for GS030 or other pipeline products.
Potential: Competition from other biotechnology companies developing similar therapies.
Ongoing: Limited financial resources and reliance on external funding.
Ongoing: Manufacturing challenges and scalability issues.

GSGTF的核心优势是什么？

Proprietary gene therapy technology platforms.
Lead product candidate in Phase III clinical trials.
Focus on rare diseases with unmet medical needs.
Experienced management team with expertise in gene therapy development.

GSGTF的劣势是什么？

Limited financial resources.
Reliance on a single lead product candidate.
High research and development costs.
Negative profit margin.

GSGTF有哪些机遇？

Expansion into new therapeutic areas.
Strategic partnerships and collaborations.
Advancements in gene therapy technology.
Geographic expansion into new markets.

GSGTF面临哪些威胁？

Regulatory hurdles and delays.
Competition from other biotechnology companies.
Clinical trial failures.
Manufacturing challenges.

GSGTF的竞争对手是谁？

AGY Therapeutics — Focuses on developing therapies for neurodegenerative diseases. — (AGYTF)
American CryoStem Corporation — Develops regenerative medicine therapies. — (AVCTF)
Bio-jet Fuel Technology, Inc. — Unrelated business; focus is on biofuel technology. — (BJTRF)
BiondVax Pharmaceuticals Ltd — Develops vaccines for infectious diseases. — (BOVNF)
BPM Minerals Ltd — Unrelated business; focus is on mineral exploration. — (BPMUF)

Key Metrics

MoonshotScore: 51/100

Company Profile

CEO: Laurence Rodriguez
Headquarters: Paris, FR
Employees: 16
Founded: 2018

AI Insight

AI analysis pending for GSGTF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does GenSight Biologics S.A. do?

GenSight Biologics S.A. is a clinical-stage biotechnology company specializing in the development of gene therapies for mitochondrial and neurodegenerative diseases, primarily targeting the eye. Their lead product, LUMEVOQ (GS010), is in Phase III clinical trials for Leber Hereditary Optic Neuropathy (LHON), a rare genetic disease causing vision loss. The company utilizes gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms to deliver functional genes directly to affected cells, aiming to restore or improve visual function. GenSight is also developing GS030 for retinitis pigmentosa and exploring treatments for other ophthalmic and neurodegenerative conditions.

What do analysts say about GSGTF stock?

As of March 16, 2026, there is no readily available analyst consensus on GSGTF stock due to its OTC listing and limited coverage. Key valuation metrics, such as the P/E ratio of -0.71 and a negative profit margin of -1600.0%, reflect the company's current stage of development and lack of profitability. Growth considerations revolve around the successful completion of clinical trials, regulatory approvals, and commercialization of LUMEVOQ and other pipeline products. The company's future prospects depend on its ability to secure funding, navigate regulatory hurdles, and compete in the gene therapy market. Investors should conduct their own thorough research and consider the risks associated with investing in a clinical-stage biotechnology company.

What are the main risks for GSGTF?

The main risks for GenSight Biologics S.A. include regulatory hurdles and potential delays in obtaining approvals for LUMEVOQ and other pipeline products. Clinical trial failures represent a significant risk, as the company's success depends on the efficacy and safety of its therapies. Competition from other biotechnology companies developing similar treatments poses a threat to market share. The company's limited financial resources and reliance on external funding create financial risks. Manufacturing challenges and scalability issues could also hinder the commercialization of its products. Investing in GSGTF carries the inherent risks associated with clinical-stage biotechnology companies, including the uncertainty of regulatory approvals, clinical trial outcomes, and market acceptance.